Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia - PubMed (original) (raw)

. 2014 Feb;164(3):384-95.

doi: 10.1111/bjh.12634. Epub 2013 Oct 30.

Affiliations

Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia

Richard Mitchell et al. Br J Haematol. 2014 Feb.

Abstract

Acute leukaemia or advanced myelodysplastic syndrome (MDS ≥ 5% blasts) in Fanconi anaemia (FA) patients is associated with a poor prognosis. We report 21 FA patients with acute leukaemia or advanced MDS who underwent haematopoietic cell transplantation (HCT) at the University of Minnesota between 1988 and 2011. Six patients had biallelic BRCA2 mutations. Eight patients received pre-transplant cytoreduction, with 3 achieving complete remission. HCT donor source included human leucocyte antigen-matched sibling (n = 2) or alternative donors (n = 19). Neutrophil engraftment was 95% for the entire cohort, and the incidence of acute graft-versus-host disease was 19%. 5-year overall survival (OS) was 33%, with a relapse rate of 24%, with similar OS in patients with biallelic BRCA2 mutations. Our study supports the use of HCT in the treatment of FA patients with acute leukaemia or advanced MDS, however, the role of chemotherapy prior to HCT remains unclear for this population. FA patients with biallelic BRCA2 are unique and may benefit from higher dose chemotherapy relative to other complementation groups.

Keywords: Fanconi anaemia; leukaemia; myelodysplastic syndrome; transplantation.

© 2013 John Wiley & Sons Ltd.

PubMed Disclaimer

Conflict of interest statement

Disclaimer

The authors have no conflict of interest to declare.

Figures

Figure 1

Figure 1

5 year overall survival and relapse for the cohort

References

    1. Alter BP. Cancer in Fanconi anemia, 1927–2001. Cancer. 2003;97:425–440. -PubMed
    1. Alter BP. The association between FANCD1/BRCA2 mutations and leukaemia. Br J Haematol. 2006;133:446–448. author reply 448. -PubMed
    1. Alter BP, Caruso JP, Drachtman RA, Uchida T, Velagaleti GV, Elghetany MT. Fanconi anemia: myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet. 2000;117:125–131. -PubMed
    1. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cytogenet. 1991;51:1–12. -PubMed
    1. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989;73:391–396. -PubMed

MeSH terms

LinkOut - more resources